Vivos Therapeutics, Inc. (VVOS)
NASDAQ: VVOS · Real-Time Price · USD
2.340
-0.080 (-3.31%)
At close: Nov 14, 2025, 4:00 PM EST
2.310
-0.030 (-1.28%)
After-hours: Nov 14, 2025, 7:58 PM EST
Vivos Therapeutics Revenue
Vivos Therapeutics had revenue of $3.82M in the quarter ending June 30, 2025, a decrease of -5.77%. This brings the company's revenue in the last twelve months to $14.39M, up 2.65% year-over-year. In the year 2024, Vivos Therapeutics had annual revenue of $15.03M with 8.91% growth.
Revenue (ttm)
$14.39M
Revenue Growth
+2.65%
P/S Ratio
1.31
Revenue / Employee
$132,046
Employees
109
Market Cap
17.56M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 15.03M | 1.23M | 8.91% |
| Dec 31, 2023 | 13.80M | -2.22M | -13.87% |
| Dec 31, 2022 | 16.02M | -861.00K | -5.10% |
| Dec 31, 2021 | 16.89M | 3.82M | 29.23% |
| Dec 31, 2020 | 13.07M | 1.67M | 14.68% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
VVOS News
- 11 days ago - Vivos Therapeutics, Inc. (VVOS) Shareholder/Analyst Call Prepared Remarks Transcript - Seeking Alpha
- 6 weeks ago - Vivos Therapeutics Releases Additional Clinical Data Showing Marked Improvement in Pediatric ADHD from Use of Vivos DNA Device - GlobeNewsWire
- 2 months ago - Vivos Therapeutics Announces Landmark Clinical Trial Results in Pediatric Obstructive Sleep Apnea Treatment - GlobeNewsWire
- 3 months ago - Vivos Therapeutics, Inc. (VVOS) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 3 months ago - Vivos Therapeutics Reports Second Quarter 2025 Financial Results and Provides Operational Update - GlobeNewsWire
- 3 months ago - Vivos Therapeutics Schedules Release of Second Quarter 2025 Financial Results and Conference Call - GlobeNewsWire
- 5 months ago - New Clinical Trial Data Published Showing Positive Results from Use of Vivos Technology to Treat Obstructive Sleep Apnea in Children - GlobeNewsWire
- 6 months ago - Vivos Therapeutics, Inc. (VVOS) Q1 2025 Earnings Call Transcript - Seeking Alpha